CASR and colonic neoplasm: Activation of the CaSR with positive allosteric CaSR modulators (calcimimetics) enhanced several inflammatory pathways in CaSR-transfected colon cancer cells, while treatment with negative allosteric CaSR modulators (calcilytics) prevented this upregulation [13,14].